Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.

Petri AL, Simonsen AH, Høgdall E, Christensen IJ, Kjaer SK, Yip C, Risum S, Pedersen AT, Hartwell D, Fung ET, Høgdall C.

Proteomics Clin Appl. 2010 Mar;4(3):304-14. doi: 10.1002/prca.200900042. Epub 2010 Jan 4.

PMID:
21137051
2.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
3.

Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.

Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C.

Acta Obstet Gynecol Scand. 2009;88(1):18-26. doi: 10.1080/00016340802443830.

PMID:
19023702
4.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.

5.

Plasma proteomic pattern as biomarkers for ovarian cancer.

Lin YW, Lin CY, Lai HC, Chiou JY, Chang CC, Yu MH, Chu TY.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46.

PMID:
16515582
6.

Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics.

Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Zivny J, Petrak J.

Oncol Rep. 2012 Feb;27(2):318-24. doi: 10.3892/or.2011.1513. Epub 2011 Oct 21.

PMID:
22020625
7.

[Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].

Petri AL, Høgdall E, Engelholm SA, Christensen IJ, Kjaer SK, Høgdall CK.

Ugeskr Laeger. 2007 Aug 13;169(33):2614-9. Review. Danish.

PMID:
17725906
8.

Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer.

No JH, Jeon YT, Kim YB, Song YS.

Gynecol Obstet Invest. 2011;71(2):136-40. doi: 10.1159/000316049. Epub 2010 Dec 14.

PMID:
21160138
9.

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88. doi: 10.1007/s00432-009-0755-5. Epub 2010 Jan 16.

10.

Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.

Arakawa N, Miyagi E, Nomura A, Morita E, Ino Y, Ohtake N, Miyagi Y, Hirahara F, Hirano H.

J Proteome Res. 2013 Oct 4;12(10):4340-50. doi: 10.1021/pr400282j. Epub 2013 Aug 29.

PMID:
23805888
11.

Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.

Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M.

Int J Gynecol Cancer. 2010 Dec;20(9):1498-505. doi: 10.1111/IGC.0b013e3181f936e3.

PMID:
21119365
12.

Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.

Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.

Acta Obstet Gynecol Scand. 2008;87(11):1136-42. doi: 10.1080/00016340802478158.

PMID:
18951217
13.

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.

Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW.

Clin Cancer Res. 2006 Jan 15;12(2):432-41.

14.
15.

Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy ST, Farias-Eisner R.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8. Epub 2003 Oct 1.

16.

HE4 in ovarian cancer: from discovery to clinical application.

Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G.

Adv Clin Chem. 2011;55:1-20. Review.

PMID:
22126021
17.

Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.

Camlica H, Duranyildiz D, Tas F, Yasasever V.

Am J Clin Oncol. 2008 Dec;31(6):585-8. doi: 10.1097/COC.0b013e318174dbd2.

PMID:
19060592
18.

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ, Berchuck A.

Gynecol Oncol. 2008 Sep;110(3):374-82. doi: 10.1016/j.ygyno.2008.04.041. Epub 2008 Jun 27.

PMID:
18584856
19.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
20.

A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.

Risum S, Høgdall E, Engelholm SA, Fung E, Lomas L, Yip C, Petri AL, Nedergaard L, Lundvall L, Høgdall C.

Int J Gynecol Cancer. 2009 Dec;19(9):1535-8. doi: 10.1111/IGC.0b013e3181a840f5.

PMID:
19955932
Items per page

Supplemental Content

Write to the Help Desk